---
title: "YZYBIO-B released its interim results, with a net loss of 58.834 million yuan, narrowing by 25% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254590888.md"
description: "YZYBIO-B announced its interim results for the period ending June 30, 2025, with revenue of 37.187 million yuan and a net loss of 58.834 million yuan, a year-on-year narrowing of 25%. The basic loss per share is 0.30 yuan. Revenue sources include licensing fee income and R&D service income, with licensing fee income of 4.7 million yuan and R&D service income of 32.5 million yuan"
datetime: "2025-08-26T09:46:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254590888.md)
  - [en](https://longbridge.com/en/news/254590888.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254590888.md)
generator: "portal-rs"
---

# YZYBIO-B released its interim results, with a net loss of 58.834 million yuan, narrowing by 25% year-on-year

According to the Zhitong Finance APP, YZYBIO-B (02496) announced its performance for the six months ending June 30, 2025, with revenue of RMB 37.187 million; a net loss of RMB 58.834 million, narrowing by 25% year-on-year; and a basic loss per share of RMB 0.30.

During the reporting period, revenue included: licensing fee income and R&D service income. The licensing fee income mainly comes from a licensing cooperation agreement signed with Chia Tai Tianqing. For the six months ending June 30, 2025, the group recognized revenue of RMB 4.7 million for the granted licensing rights to achieve development milestones.

The R&D service income primarily arises from the commissioned R&D services provided to Chia Tai Tianqing based on the licensing cooperation agreement. For the six months ending June 30, 2025, the company recognized RMB 32.5 million of R&D service income based on the relative proportion of efforts or inputs expended to meet the performance obligations compared to the total expected inputs required to fulfill those obligations

### Related Stocks

- [02496.HK](https://longbridge.com/en/quote/02496.HK.md)

## Related News & Research

- [Hyundai Fights Childhood Cancer — But How Much Does It Really?](https://longbridge.com/en/news/298381143.md)
- [Sepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/298745982.md)
- [Ju Fu Tang Biotech holds annual shareholder meeting](https://longbridge.com/en/news/298578782.md)
- [LongBio Pharma names Xue Kailu non-executive director after EGM vote](https://longbridge.com/en/news/298597482.md)
- [Shanghai Haohai files HKEX next-day return disclosing share buyback for cancellation](https://longbridge.com/en/news/298427542.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**